“…Although this route offers a gender-specific treatment of systemic or local, female-related conditions (2,3), the merits of vaginal administration such as the avoidance of hurdles associated with per-oral or parenteral application (i.e., drug hepatotoxicity, first-pass drug metabolism, drug plasma concentrations fluctuations, side effects, inconvenience, irritation of gastrointestinal mucosa; 2) enable prolonged dosing with lower daily doses of drugs applied in controlled-release delivery systems (1). Achieving comparable pharmacodynamic effects by vaginal route as by per-oral drug delivery provides indirect proof of effective drug absorption through vaginal mucosa owing to its high absorptive surface area, rich blood supply, significantly diminished expression of phase I and II metabolizing enzymes and transporters, and sufficient permeability to drugs (4)(5)(6)(7)(8)(9)(10).…”